Jonathan M Meyer, Craig Chepke, Rimal B Bera, M Mercedes Pérez-Rodríguez, Leslie Lundt, Ericha G Franey, Rahul Dhanda, Betsy Benning, Morgan Bron, Chuck Yonan
INTRODUCTION: Two vesicular monoamine transporter 2 (VMAT2) inhibitors are approved in the United States (US) for the treatment of tardive dyskinesia (TD). There is a paucity of information on the impact of VMAT2 inhibitor treatment on patient social and physical well-being. The study objective was to elucidate clinician-reported improvement in symptoms and any noticeable changes in social or physical well-being in patients receiving VMAT2 inhibitors. METHODS: A web-based survey was offered to physicians, nurse practitioners, and physician assistants based in the US who prescribed valbenazine for TD within the past 24 months...
October 2023: Mental Health Clinician